Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19

The recent pandemic of COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an extraordinary challenge to identify effective drugs for prevention and treatment. The pathogenesis implicate acute respiratory disorder (ARD) which is attributed to significan...

Descripción completa

Detalles Bibliográficos
Autores principales: S, Sugin Lal Jabaris, V, Ranju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833560/
https://www.ncbi.nlm.nih.gov/pubmed/33259924
http://dx.doi.org/10.1016/j.pupt.2020.101978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833560/
https://www.ncbi.nlm.nih.gov/pubmed/33259924
http://dx.doi.org/10.1016/j.pupt.2020.101978

Ejemplares similares